Amgen (AMGN34) – tečaj delnic in novice

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia

Vizitka: Amgen

Generalni direktorRobert A. Bradway

Št. zaposlenih31,5 tis.

Ustanovljeno1980

SedežThousand Oaks, Kalifornija, Združene države Amerike

SektorHealth Care

Panoga-

Spletno mestoamgen.com

Vse vrednosti v valuti USD	dec. 2025	mar. 2026	jun. 2026	sep. 2026
Prihodek	9,87 mrd.	8,62 mrd.	10,05 mrd.	10,36 mrd.
Strošek prodanega blaga	2,68 mrd.	2,50 mrd.	2,75 mrd.	2,79 mrd.
Stroški materiala in storitev	2,68 mrd.	2,50 mrd.	2,75 mrd.	2,79 mrd.
Stroški raziskav in razvoja	2,14 mrd.	1,72 mrd.	1,87 mrd.	2,11 mrd.
Skupni stroški raziskav in razvoja	-	-	-	-
Stroški prodaje, splošni in administrativni stroški	1,95 mrd.	1,60 mrd.	1,74 mrd.	1,68 mrd.
Operativni strošek	4,18 mrd.	3,21 mrd.	3,73 mrd.	3,87 mrd.
Skupni operativni stroški	6,85 mrd.	5,70 mrd.	6,48 mrd.	6,66 mrd.
Prihodek iz poslovanja	3,01 mrd.	2,91 mrd.	3,57 mrd.	3,71 mrd.
Drug prihodek, ki ne izhaja iz poslovanja	143,00 mio.	192,00 mio.	145,00 mio.	127,00 mio.
Zaslužek pred obdavčitvijo z vključenimi izrednimi postavkami	1,51 mrd.	2,08 mrd.	2,77 mrd.	4,69 mrd.
Zaslužek pred obdavčitvijo brez izrednih postavk	2,51 mrd.	2,37 mrd.	3,06 mrd.	3,19 mrd.
Odhodek iz obdavčitve dobička	181,00 mio.	265,00 mio.	393,00 mio.	822,00 mio.
Dejanska davčna stopnja	11,96 %	12,72 %	14,20 %	17,54 %
Drugi operativni stroški	82,00 mio.	−113,00 mio.	116,00 mio.	76,00 mio.
Čisti prihodek	1,33 mrd.	1,82 mrd.	2,38 mrd.	3,86 mrd.
Neto stopnja dobička	13,51 %	21,11 %	23,62 %	37,28 %
Čisti dobiček na delnico	5,29	5,15	6,29	6,45
Prihodki iz obresti in naložb	408,00 mio.	-	-	-
Obrestni odhodki	−1,06 mrd.	−657,00 mio.	−673,00 mio.	−653,00 mio.
Neto obrestni odhodki	−653,00 mio.	−657,00 mio.	−673,00 mio.	−653,00 mio.
Stroški amortizacije	-	-	-	-
EBITDA	4,02 mrd.	4,03 mrd.	4,69 mrd.	4,83 mrd.
Dobiček ali izguba pri prodaji sredstev	-	-	-	-

Vprašajte kar koli